The approval is expected to support the company’s presence in regulated international markets and further strengthen its position as a reliable pharma manufacturing partner
The aflibercept biosimilar, referencing Eylea, becomes the company’s fifth directly commercialized biosimilar in Europe, expanding access to ophthalmology treatments
If approved, TEV-‘749 would mark a shift toward long-acting care aimed at improving treatment adherence in real-world settings
Stroke is the second-leading cause of death and the third-leading cause of disability worldwide
His appointment is expected to further strengthen the company’s financial governance and regional operational strategy across South Asia
The results signal shift beyond paclitaxel-coated balloon (PCB) angioplasty in femoropopliteal artery disease
The SirPAD trial marks a significant milestone in vascular intervention, positioning MagicTouch PTA as a promising future alternative for PAD treatment
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpoints
If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations
Subscribe To Our Newsletter & Stay Updated
